A phase I/II trial dose escalation study of a Vero cell-derived, whole virus H5N1 influenza vaccine in healthy volunteers aged 18 to 45 years

Trial Profile

A phase I/II trial dose escalation study of a Vero cell-derived, whole virus H5N1 influenza vaccine in healthy volunteers aged 18 to 45 years

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Influenza A vaccine H5N1-Baxter (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 18 Jun 2008 Phase I/II endpoints for safety and immunogenicity have been met, according to information from a Baxter media release.
    • 12 Jun 2008 Results have been published in the New England Journal of Medicine.
    • 28 Mar 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top